ALPS Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-104,058
| Closed | -$4.19M | – | 1172 |
|
|
2026
Q1 | $4.19M | Buy |
104,058
+362
| +0.3% | +$7.8K | 0.02% | 278 |
|
|
2025
Q4 | $2.6M | Buy |
103,696
+40,881
| +65% | +$959K | 0.02% | 350 |
|
|
2025
Q3 | $1.42M | Sell |
62,815
-4,946
| -7% | -$115K | 0.01% | 445 |
|
|
2025
Q2 | $1.17M | Buy |
+67,761
| New | +$1.25M | 0.01% | 469 |
|
|
2021
Q4 | – | Sell |
-106,632
| Closed | -$3.52M | – | 893 |
|
|
2021
Q3 | $3.52M | Buy |
106,632
+1,008
| +1% | +$56.6K | 0.03% | 198 |
|
|
2021
Q2 | $6.67M | Sell |
105,624
-31,395
| -23% | -$1.62M | 0.06% | 161 |
|
|
2021
Q1 | $5.88M | Buy |
137,019
+365
| +0.3% | +$17.3K | 0.06% | 167 |
|
|
2020
Q4 | $7.82M | Buy |
136,654
+40,239
| +42% | +$1.7M | 0.09% | 150 |
|
|
2020
Q3 | $2.91M | Sell |
96,415
-6,598
| -6% | -$197K | 0.04% | 193 |
|
|
2020
Q2 | $3.36M | Sell |
103,013
-30,505
| -23% | -$980K | 0.05% | 183 |
|
|
2020
Q1 | $3.58M | Buy |
133,518
+4,822
| +4% | +$171K | 0.06% | 169 |
|
|
2019
Q4 | $3.94M | Buy |
128,696
+1,640
| +1% | +$45.4K | 0.03% | 174 |
|
|
2019
Q3 | $3.06M | Sell |
127,056
-5,295
| -4% | -$146K | 0.02% | 182 |
|
|
2019
Q2 | $3.35M | Sell |
132,351
-3,497
| -3% | -$71.1K | 0.02% | 179 |
|
|
2019
Q1 | $2.65M | Buy |
135,848
+5,875
| +5% | +$92.4K | 0.02% | 200 |
|
|
2018
Q4 | $1.71M | Buy |
129,973
+30,560
| +31% | +$469K | 0.01% | 233 |
|
|
2018
Q3 | $1.77M | Buy |
99,413
+18,231
| +22% | +$337K | 0.01% | 266 |
|
|
2018
Q2 | $1.79M | Buy |
+81,182
| New | +$1.87M | 0.01% | 241 |
|
Other funds holding APLS
ALPS Advisors's APLS Position: Q2 2026 in Review
ALPS Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 104,058 shares — an estimated $4.19M sold.
ALPS Advisors first reported a position in APLS in Q2 2018 and held it in 18 quarters. The position peaked at $7.82M in Q4 2020. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- ALPS Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- ALPS Advisors sold 104,058 Apellis Pharmaceuticals shares in Q2 2026, an estimated $4.19M.
- ALPS Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 18 quarters.
- ALPS Advisors's Apellis Pharmaceuticals position peaked at $7.82M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.